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economic analysis of the HomePAP study, a multi-center randomized clinical trial
that compared home-based versus lab-based testing for themanagement of OSA in
accredited sleep centers. METHODS: A total of 373 subjects with a high risk for
moderate to severe OSA were randomized to either unattended, home-based lim-
ited channel portable monitoring for diagnosis of OSA followed by unattended
auto-titration with continuous positive airway pressure (CPAP), versus a tra-
ditional pathway of in-laboratory sleep study and CPAP titration. Given that 3
month outcomes were not inferior for the home arm in acceptance, adherence,
and functional improvements, we pursued a cost minimization analysis from
the payer perspective. 2011 Medicare price weights were used. Interpretation of
home-based CPAP titration is currently not reimbursed by Medicare, so we es-
timated it as one-third the Medicare reimbursement for interpreting a lab-based
sleep study. RESULTS: Per subject costs, as randomized, were $1265 for the lab-
based pathway and $927 for the home-based pathway (base case). In the per pro-
tocol analysis (patients adherent to CPAP for 3months), per subject costswere even
higher for the lab-based pathway ($1,863 vs. $866). In a sensitivity analysis, even
after increasing the Medicare reimbursement for home-based titration studies to
100% that of lab-based studies, per subject costs per protocol were still higher for
the lab-based pathway ($1,863 vs. $953). CONCLUSIONS: From the payer perspec-
tive, there are higher costs incurred within a lab-based versus a home-based diag-
nostic pathwaywithout superiority in outcomes. The results suggest that the care-
ful use of home-based sleep studies administered by trained personnel at board-
certified sleep centers could save money without compromising short term
outcomes.
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OBJECTIVES: Improvement in glycaemic control associated with Continuous Glu-
cose Monitoring (CGM) use leads to a reduction of costly diabetes-related compli-
cations. Our aim was to estimate the health economics benefits of CGM compared
to Self-Monitoring of Blood Glucose (SMBG) in type 1 diabetes (T1DM) in the Swed-
ish setting.METHODS: The Core DiabetesModel (CDM) is an internet-based, highly
validated, computer-simulation model to determine the long-term health out-
comes and economic consequences of diabetes interventions. This model was
used to evaluate the cost-effectiveness of CGM versus SMBG in T1DM over a life-
time horizon. Results from a recently published meta-analysis comparing CGM
versus SMBG and a real life observational Swedish study were used. The meta-
analysis showed that for a cohort of T1DM with average baseline HbA1c of 8.1%,
mean baseline age of 27 years and diabetes duration of 13 years, everyday use of
CGM led to HbA1c reduction of -0.76% versus -0.13%, for CGM and SMBG respec-
tively. The observational study demonstrated a reduction from 7.11 to 4.35 daily
blood glucose tests when using CGM compared to SMBG only. RESULTS: The Incre-
mental-Cost-Effectiveness-Ratio (ICER) for CGM vs. SMBG only was 369,253SEK
(41,940€) per Quality-Adjusted-Life-Year gained (QALYg), based on combined direct
and indirect costs. Undiscounted life expectancy was improved by 1.5 years. The
improvement in discounted QALY was 0.62 in favour of CGM. CGM related costs
were partially offset by the savings due to the reduction in long-term complica-
tions. CGM usage compared to SMBG increased the mean time alive free from
complications. Sensitivity analysis has been conducted. CONCLUSIONS: Our anal-
ysis showed that CGM is very cost-effective compared to SMBG over a lifetime
horizon in T1DM patients in the Swedish setting and can lead to an increase in life
expectancy.
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OBJECTIVES: To estimate the cost-effectiveness of delayed troponin testing for
myocardial infarction (MI), as recommended in current guidelines, compared to
troponin testing at presentation. METHODS: We developed a decision analytic
model to estimate the cost-effectiveness of diagnostic strategies for MI, measured
as the incremental cost per quality-adjusted life year (QALY) gained by each strat-
egy compared to the next most effective alternative. The model was applied to a
hypothetical population of 1000 patients attending hospital with symptoms sug-
gesting MI but a normal or non-diagnostic electrocardiogram (ECG) and no major
co-morbidities requiring hospital treatment. Delayed troponin testing (10-12 hours
after symptom onset) was compared to standard and high sensitivity troponin
testing at presentation and no testing. We tested three different scenarios regard-
ing delayed testing, in relation to the delay between results being available and a
decision beingmade, the “doctor on demand” scenario, inwhichmedical staffwere
available 24 hours a day to make a disposition decision within one hour of the
results being available, twice daily ward round and once daily ward round scenar-
ios where medical staff were only available at twice daily ward rounds and once
dailyward rounds, respectively. RESULTS: In all scenarios tested presentation high
sensitivity troponin testing was the most effective strategy with an incremental
cost-effectiveness ratio (ICER) below the £20,000/QALY threshold. Delayed tro-
ponin testing was only likely to be cost-effective if a discharge decision could be
made as soon as a negative result was available and the £30,000/QALY threshold
was used. CONCLUSIONS: Delayed troponin testing is unlikely to be cost-effective
compared to high sensitivity troponin testing at presentation in most scenarios.
The current guidelines recommending 10-12 hour troponin testing does not appear
to promote cost-effective use of hospital resources, unless services are in place to
allow rapid decision making once delayed test results are available.
PMD41
INSULIN PUMP COST-UTILITY ANALYSIS COMPARED TO MULTIPLE DAILY
INJECTION IN TYPE 1 DIABETIC PATIENTS IN THE MEXICAN SOCIAL SECURITY
INSTITUTE, 21ST CENTURY HOSPITAL
Quiroz M1, Machado F2, Shafiroff J3, Gill M3, Molina M4, Gonzalez P5
1Medtronic Mexico, col Cuahutemoc Delegacion Benito Juarez, DF, Mexico, 2Medtronic, Miami, FL,
USA, 3Medtronic Diabetes, Northridge, CA, USA, 4Instituto Mexicano del Seguro Social, Mexico
City, DF, Mexico, 5Medtronic Iberia, Madrid, Madrid, Spain
OBJECTIVES: To estimate the clinical and economic consequences of Continuous
Subcutaneous Insulin Infusion (CSII) versus Multiple Daily Injection (MDI) for type
1 diabetes (DM1) through cost-utility analysis, from the perspective of the Mexican
Social Security Institute (IMSS).METHODS:We used a validated simulation model
(CORE Model), together with published literature for clinical, quality of life and
therapy effectiveness. Demographic information and incident complications for
131 patients with DM1 from the 21st Century Hospital (IMSS) were incorporated
into the simulation. Direct and indirect cost data were obtained from the IMSS and
Secretary of Health (SSA) National Economic Information. A simulation of the clin-
ical and economic consequences in a lifetime follow-up of therapy was performed.
Direct and indirect costs with a discount rate of 3% were input to the model.
RESULTS: Lifetime, treatmentwithCSII gained 8.5 quality-adjusted life years vs. 7.6
quality-adjusted life years for MDI therapy. Over 50 years of treatment, CSII versus
MDI, had an incremental direct cost of 422,187 Mexican Pesos (MXP) per quality
adjusted life year (QALY). For indirect costs, CSII is cost saving relative to MDI
(saving 158,831 MXP/QALY). For combined direct and indirect costs, the incremen-
tal cost-effectiveness ratio for CSII vs. MDIwas 283,356MXP/QALY.CONCLUSIONS:
Better glycemic control, and increased quality of life for DM1 patients treated with
CSII demonstrated incremental cost effectiveness below the willingness to pay
threshold set by the World Health Organization (510,300 MXP). This makes CSII a
cost effective treatment alternative to MDI in Mexico. The higher incremental di-
rect cost of CSII relative to MDI is compensated by the savings in indirect costs.
MEDICAL DEVICE/DIAGNOSTICS – Patient-Reported Outcomes & Patient
Preference Studies
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OBJECTIVES: Back and leg pain arising from spinal stenosis with degenerative
spondylolisthesis have a substantial impact on the quality of life of patients. Using
data on collected costs, resource utilization, and patient-reported outcomes from
an ongoing randomized clinical trial comparing a novel, motion-preserving inter-
laminar stabilization device (coflex®) to control (instrumented posterolateral spi-
nal fusion) among patients with spinal stenosis and spondylolisthesis, we report
and compare the relative cost-effectiveness of these two treatments.METHODS: A
model was developed to compare interventions. The primary source for the mod-
el’s clinical input parameterswas the recent investigational clinical trial of coflex®,
supporting premarket approval application to FDA. Treatment patterns over five
years were estimated based on claims data analyses and expert opinion. Oswestry
Disability Index scores collected during the trial were converted to utilities. A third-
party payer perspective was used, and costs (US 2011$) and outcomes were dis-
counted at 3% annually. Both Medicare and private-payer costs were modeled.
Sensitivity analyses examined the influence of costs, utilities, and discount rates.
RESULTS: Patients receiving coflexhadhigher success rates and lower costs in both
theMedicare and private payermodels. Payments over five yearswere estimated at
$14,534 for coflex® implant patients compared to $25,620 for controls (Medicare
costs; $17,714 vs. $31,747 for private coverage). Utilities were higher for coflex®-
treated patients at all assessments, and totaled 3.03 quality-adjusted life years
(QALY) compared to 2.98 for controls. Incremental cost-effectiveness could not be
calculated, as the novel implant dominated, demonstrating both lower costs and
better outcomes. Sensitivity analyses identified no scenario in which fusion was
preferred over the coflex®. CONCLUSIONS: The use of coflex® to treat stenosis and
spondylolisthesis is cost saving, and associated with improved patient outcomes.
Subgroup analyses comparing indications and patient characteristics should be
conducted to confirm robustness of findings.
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OBJECTIVES: Current multiple sclerosis (MS) disease modifying medications fre-
quently require the use of self-injection devices. These can present varied burdens
for patients in terms of their portability, complexity in preparation and potential
for causing discomfort. Furthermore, the necessity to self-inject is closely associ-
atedwith levels of adherence to treatment and optimising the acceptability of such
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devices to patients may have a positive impact on treatment outcomes. The aim of
this study was to better understand the preferences of MS patients for attributes of
self-injection devices. METHODS: A discrete choice experiment (DCE) survey was
developed on the basis of a review of published literature. The attributes identified
for inclusion in the survey were: ease of use; comfort of use; presence of additional
functions, needle visibility; practicality and efficacy. Choice sets were presented as pairs
of hypothetical treatments based upon a fractional factorial design. One-hundred
device-using MS patients completed the survey online. Analysis was conducted
using a mixed-logit approach RESULTS: Analysis of the DCE data revealed that all
attributes significantly predicted treatment choice. As anticipated, efficacy exhib-
ited the largest effect on treatment selection and this provided context for under-
standing themagnitude of impact for the other attributes. Reducing the discomfort
associated with device use and eliminating the necessity for assembly or drug
reconstitution were highly valued by patients. The addition of reminder and time-
stamping functions, improved needlestick injury prevention and a reduction in
device size were secondary concerns but still deemed desirable. CONCLUSIONS:
Although efficacy is of primary importance to MS patients, the characteristics of
drug delivery devices can play an important role in treatment decision-making.
The findings suggest that there is significant potential value in developing self-
injection devices that are not only efficacious but also convenient and comfortable
to use. Reducing barriers to adherence could potentially translate into improved
treatment outcomes for patients with MS.
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OBJECTIVES: While a variety of knee-specific instruments currently exist, no pa-
tient-reported outcome (PRO)measures correlate functionwith improved stability,
motion, satisfaction, and confidence. The objective of our study was to address the
identified gap in available PROs assessing this phenomenon of a “normal” knee
following primary TKA.METHODS: A conceptual model linking the impact of clin-
ical mechanics to hypothesized functional outcomes was generated following a
literature review of available assessment tools. Participants aged 18 to 80 who had
undergone TKA within the past 10 to 18 months were identified through clinical
sites to participate in Phase 1) focus groups, or Phase 2) in-depth interviews. Par-
ticipants were asked to describe experiences with their knee replacement and
general questions about how their knee feels now, since they had the surgery,
followed by cognitive debriefing of the draft items. Specific inclusion and exclusion
criteria were developed in addition to a semi-structured interview guide. Constant
comparative analysis was employed to identify key points and compared across all
results to observe themes in participant experiences. RESULTS: Results from the
first phase of the project indicated that the concepts of confidence, stability, and
satisfaction in their replacement kneewhenperforming activities requiring certain
motions were felt to be distinct from each other and important in the patients’
assessment of their TKA. Phase 2 efforts yielded a final version of the PKIP scale
containing 9 items assessing the broader concepts of stability, confidence and
satisfaction in association with activities. Both a pre and post-surgical version of
themeasurewere created.CONCLUSIONS:Results of this qualitative study support
the use of the PKIP to assess performance following primary TKA. Psychometric
evaluation of the PKIP is planned.
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OBJECTIVES: It is not clearly establishedwhether percutaneous coronary interven-
tion (PCI) provides similar incremental benefit in terms of health related quality of
life (HRQoL) among all patients.METHODS:We analyzed 795 consecutive patients
undergoing PCI at our institution. Health outcomes was estimated in terms of
quality adjusted life years (QALYs) gainedmeasured using EQ-5D at baseline, 6 and
12 months after PCI. Change in QALY at 1 year was compared between different
subgroups. The Canadian Cardiac Society (CCS) Classification of angina symptom
was used. RESULTS: Overall mean EQ-5D utility scores were higher at 6 (0.860.22)
and 12months (0.790.21) than at baseline (0.440.42) andmeanQALY gainedwas
0.39. Patients who underwent rescue PCI (QALY gain 0.74), primary PCI for STEMI
(0.49) and left main coronary artery intervention (0.57) experienced the highest
gain in QALY. There was progressive increase in QALY gain for patients with CCS 1
(0.24), 2 (035), 3 (0.45) and 4 (0.49) angina symptoms (p0.01). Females (0.43) expe-
rienced greater gain in QALY than males (0.38). QALY gain was higher in patients
who had PCI to 3- (0.43) than in 2- (0.40) and 1-vessel (0.39, p0.01). There were no
differences in QALY gain between patients 40-60, 60-80 and80 years old. Patients
who experienced the least QALY gain had a history of renal failure (0.24), previous
PCI (0.3), failed index PCI (0.27) and chronic total occlusion intervention (0.31).
Patients who required repeat PCI during follow-up had lower QALY gain (0.32)
compared to those without (0.40). CONCLUSIONS: Despite overall improvement in
health status, there was significant variation in the magnitude of quality of life
improvement among different patient subgroups after PCI.
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OBJECTIVES: To determine the effect of adjusting colorectal-cancer (CRC) screen-
ingwillingness-to-pay (WTP) estimates for uptake bias fromyea-saying in a choice-
format conjoint-analysis study.Yea-saying refers to a tendency to express agree-
ment regardless of one’s actual views when responding to hypothetical questions.
Screening tests offer an opportunity to compare stated and actual uptake rates.
METHODS:Adults aged 45-70 yearswith no history of CRC and physicians from the
United States and Canada completed aweb-enabled choice-format conjoint survey
that presented subjects with pairs of profiles for screening tests. Test features
included test type, frequency, accuracy, and cost. Each test-preference question
was followed by a question asking if the respondent preferred no screening to the
chosen test. A bivariate probit model combined data from both questions. Pre-
dicted WTP conditional on purchasing a test and societal expected WTP adjusted
for uptake probabilitywere estimated for both samples. RESULTS:A total of 501 and
1,087 adults fromCanada and theUnited States respectively, and 100 physicians from
both countries completed the survey. Patients opted for a screening test in about 70%
of the questions. Physicians expected their patients to opt for a screening only 50% of
the time, which is the same as the observed uptake rate. For any given screening test,
physicians’ surrogateWTP values were significantly less than patients’ values. More-
over, patients had significantly larger divergences between conditional and expected
WTPmeasures. The US patient expectedWTP for colonoscopy, adjusted for yea-say-
ing bias in predicted uptake, was $435, which was 29% smaller than the unadjusted
expected WTP. CONCLUSIONS: If stated-preference subjects choose testing more
frequently than they would if actually offered the hypothetical alternatives, the up-
wardly biaseduptake estimatesdistort societalWTPmeasures.Minimizing incentives
for yea-saying, detecting potential bias, and adjusting resulting WTP estimates is a
high priority for stated-preference research.
MEDICAL DEVICE/DIAGNOSTICS – Health Care Use & Policy Studies
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OBJECTIVES: To explore the ways in which hospital payments can be used to
encourage cost-effective use of health technology.METHODS: A survey of the de-
velopers of hospital payment systemswas conducted in 14 jurisdictions in order to
ascertain if and how existing payment systems facilitate the adoption of new tech-
nologies, whether evidence of value (eg therapeutic benefit, cost-effectiveness) is
considered when determining codes/ tariffs, and in what ways payment systems
could be adjusted to link payment levels more closely to evidence on value for
money. RESULTS: Around 50% of the jurisdictions had developed their own pay-
ment classifications, as opposed to importing/adapting a system fromelsewhere. A
minority had created new codes/tariffs outside of a general update in response to a
new technology. Three jurisdictions used evidence of value when creating new
codes/tariffs, although they tended to only consider therapeutic benefit, not cost-
effectiveness. The main barriers to using evidence in creating new codes/tariffs
were the lack of a clear mechanism to do so, lack of standardization in the collec-
tion of hospital cost data and unclear or unavailable clinical evidence. Around 70%
of jurisdictions had used special payments, outside of the standard codes/tariffs, in
response to specific new technologies and 50%used evidence of valuewhen setting
payment levels. In the case of special payments, consideration of evidence of both
therapeutic benefit and cost-effectiveness was more common. Overall, respon-
dents felt that hospital payment systems had only amodest tomoderate impact on
the uptake of new technologies, due primarily to the time taken in establishing new
codes/tariffs, or negotiating special payments. CONCLUSIONS: Hospital payment
systems have the potential to encourage the cost-effective use of new health tech-
nologies. More attention, however, is needed regarding the procedures for updat-
ing codes/tariffs or negotiating special payments, and in particular the ways of
considering evidence of value.
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OBJECTIVES: This study evaluates the impact on market dynamics of applying
existing Health Technology Assessment (HTA) methodologies to medical devices.
METHODS: Using a case study on drug-eluting stents (DES), we examine whether
the economic characteristics of medical devices introduce particular challenges to
the application of HTA and whether the experience of DESs suggests directions for
policy formulation.RESULTS:The case study found amarket that encourages rapid
competition, leading to value for the end user though price competition. The ap-
plication of existing HTA methods has the potential to disrupt this dynamic and
reduce the rewards of medical devices to innovators - through higher evidence
requirements on initial entrants and market dynamics that subsequently drive a
reduction in prices. A cycle of price reductions results because the comparator
price of the old technology is reduced as a consequence of ‘disinvestment’ follow-
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